p70S6K/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab

Shota Fukuoka(National Cancer Research Institute), Takashi Kojima(National Cancer Center Hospital East)

Scientific Reports

September 25, 2023

10.1038/s41598-023-40612-9

Cited by 9

Related Papers

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

|Journal of Clinical Oncology|2020|1.2k

Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

|Cancer Cell|2022|828

The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

|Nature Immunology|2020|810

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus

|JAMA Oncology|2018|518